Journal ArticleDOI
Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors
TLDR
There is a growing understanding of viral, host and environmental factors influencing disease progression, which ultimately could improve the management of chronic hepatitis B.About:
This article is published in Journal of Hepatology.The article was published on 2008-02-01. It has received 1172 citations till now. The article focuses on the topics: HBeAg & Hepatitis B.read more
Citations
More filters
Journal ArticleDOI
General and abdominal adiposity and risk of death in HBV versus non-HBV carriers: A 10-year population-based cohort study
Wen-Yuan Lin,Cheng Yuan Peng,Cheng-Chieh Lin,Lance E. Davidson,F. Xavier Pi-Sunyer,Pei Kun Sung,Kuo-Chin Huang +6 more
TL;DR: In this paper, the association between general and central obesity and all-cause mortality among adult Taiwanese hepatitis B virus (HBV) versus non-HBV carriers was investigated, and Cox proportional-hazards models were used to estimate the relative risks for all cause mortality during a maximum follow-up period of 10 years.
Journal ArticleDOI
Single nucleotide polymorphisms in ZNF208 are associated with increased risk for HBV in Chinese people.
TL;DR: It is suggested that ZNF208 polymorphisms may contribute to the development of HBV.
Journal ArticleDOI
Treatment of Chronic Hepatitis B Virus with Oral Anti-Viral Therapy.
TL;DR: Nucleoside analogues are the drugs most commonly used in the treatment of chronic hepatitis B as discussed by the authors, and they act by inhibiting viral replication and have minimal impact on HBsAg loss.
Journal ArticleDOI
A Prospective Five-Year Follow-up After peg-Interferon Plus Nucleotide Analogue Treatment or no Treatment in HBeAg Negative Chronic Hepatitis B Patients
Robin Erken,Vladimir V. Lukashov,Annikki de Niet,Louis Jansen,F. Stelma,Jeltje Helder,Martine W Peters,Hans L. Zaaijer,Neeltje A. Kootstra,S.B. Willemse,Hendrik W. Reesink +10 more
TL;DR: In this paper , the long-term effect of combination treatment with peg-interferon-alpha-2a (peg-IFN) and adefovir or tenofovir compared to no treatment was evaluated.
Journal ArticleDOI
Increased Proinflammatory Cytokine Production by Chronic Hepatitis B Patients with Mutant Hepatitis B Virus: Plausible Mechanisms Underlying Severe Liver Diseases in These Patients
Ruksana Raihan,Sheikh Mohammad Fazle Akbar,Mamun Al Mahtab,Sakirul Islam Khan,Shahina Tabassum,Kok Keng Tee,Kok Keng Tee,Rosmawati Mohamed +7 more
TL;DR: The inflammatory potential of mutant HBV that may be responsible for diverse levels of pathogenicity of HBV is discussed and these insights may aid in developing immune therapy for CHB patients.
References
More filters
Journal ArticleDOI
Measuring inconsistency in meta-analyses
TL;DR: A new quantity is developed, I 2, which the authors believe gives a better measure of the consistency between trials in a meta-analysis, which is susceptible to the number of trials included in the meta- analysis.
Journal ArticleDOI
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.
Chien-Jen Chen,Hwai I. Yang,Jun Su,C.-L. Jen,San Lin You,Sheng-Nan Lu,Guan-Tarn Huang,Uchenna H. Iloeje +7 more
TL;DR: Elevated serum HBV DNA level (> or =10,000 copies/mL) is a strong risk predictor of hepatocellular carcinoma independent of HBeAg, serum alanine aminotransferase level, and liver cirrhosis.
Journal ArticleDOI
Chronic hepatitis B
Anna S. Lok,Brian J. McMahon +1 more
TL;DR: These guidelines have been written to assist physicians and other health care providers in the recognition, diagnosis, and management of patients chronically infected with the hepatitis B virus (HBV).
Journal ArticleDOI
The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide
TL;DR: HBV and HCV infections account for the majority of cirrhosis and primary liver cancer throughout most of the world, highlighting the need for programs to prevent new infections and provide medical management and treatment for those already infected.
Journal ArticleDOI
Hepatocellular carcinoma in cirrhosis: incidence and risk factors.
TL;DR: Further studies are needed to investigate other viral factors (eg, HBV genotype/mutant, occult HBV, HIV coinfection) and preventable or treatable comorbidities ( eg, obesity, diabetes) in the HCC risk in cirrhosis.